Randomized dose-response study of rosuvastatin in Japanese patients with hypercholesterolemia.

@article{Saito2003RandomizedDS,
  title={Randomized dose-response study of rosuvastatin in Japanese patients with hypercholesterolemia.},
  author={Yasushi Saito and Yuichiro Goto and Aaron L Dane and Kristina Strutt and Ali Raza},
  journal={Journal of atherosclerosis and thrombosis},
  year={2003},
  volume={10 6},
  pages={329-36}
}
Rosuvastatin is a novel statin that has been shown to produce large dose-dependent reductions in low-density lipoprotein cholesterol (LDL-C) in Western hypercholesterolemic patients. Rosuvastatin dose response was assessed in a randomized, double-blind phase II trial in which 112 Japanese patients with fasting LDL-C > 160 and < 220 mg/dl and triglycerides < 300 mg/dl received placebo or rosuvastatin 1, 2.5, 5, 10, 20, or 40 mg once daily for 6 weeks. LDL-C change from baseline showed a linear… CONTINUE READING